Industry sponsor intelligence

Tibotec Pharmaceuticals, IrelandClinical Pipeline.

Lead-sponsor view of Tibotec Pharmaceuticals, Ireland's indexed peptide studies, development phases, active programs, completed work and recent registry changes.

Total: 1
Recruiting: 0
Active: 0
Completed: 1
Results posted: 1
Avg enrollment: 211

Pipeline overview

Programs by phase and activity.

Velocity

Tibotec Pharmaceuticals, Ireland trials by start year

Study start year · indexed snapshot

Development

Trials by phase

1phase labels

Early Phase 10

Phase 10

Phase 21

Phase 30

Phase 40

Product	Studies	Early / I	Phase II	Phase III	Phase IV	Active
Enfuvirtide →	1	0	1	0	0	0

Active peptide trials

In motion now.

No studies in this snapshot.

Completed trials

Finished registry records.

NCT IDStudyPhase / statusEnrollmentUpdated

NCT00128830

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

Tibotec Pharmaceuticals, Ireland · Human Immunodeficiency Virus Type 1

Phase 2

Completed

211

2013-06

Search sponsor records

All Tibotec Pharmaceuticals, Ireland studies.

This page groups studies where Tibotec Pharmaceuticals, Ireland is listed as the lead industry sponsor. Collaborator-only records are not included in the count.

1 matching study

Last registry update first

NCT00128830Phase 2Results

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

EnfuvirtideTibotec Pharmaceuticals, IrelandHuman Immunodeficiency Virus Type 1

Completed

Enrollment: 211
Started: Jun 2005
Completion: Aug 2008
Locations: 0
Countries: 0
Updated: Jun 2013

End of 1 results

Recent updates

Latest registry movement.

NCT00128830A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 StudyJun 20, 2013